Cancer biologics Market Forecast Signals New Revenue Opportunities Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Cancer biologics Market Expected To Reach $203.28 Billion By 2030 At 9.6% CAGR
The market for cancer biologics has experienced robust expansion in recent times. Its value is projected to increase from $129.05 billion in 2025 to $140.88 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.2%. This historical growth has been driven by factors such as the global rise in cancer incidence, heightened demand for sophisticated cancer treatments, intensified efforts in oncology research, the constrained efficacy of traditional chemotherapy, and the proliferation of hospital-based cancer care facilities.
The cancer biologics market is projected to experience robust expansion over the coming years, reaching $203.29 billion by 2030 with a compound annual growth rate (CAGR) of 9.6%. This projected growth during the forecast period is driven by progress in cell and gene therapy platforms, the growing number of approvals for new biologic drugs, the rise of personalized oncology approaches, increased funding for cancer biologics research and development, and the scaling up of biologics production capabilities. Key developments expected to shape this period include the increasing use of immunotherapy and targeted biologic therapies, the broader application of monoclonal antibodies in cancer treatment, the emergence of cell and gene therapy-based oncological interventions, the advancement of cancer vaccine initiatives, and a heightened emphasis on precision biologic strategies.
Download A Free Sample Report For Comprehensive Market Insights:
Cancer biologics Market Demand Drivers Creating New Revenue Opportunities
The increasing occurrence of chronic illnesses is a key factor fueling expansion in the cancer biologics market. These conditions, which last for extended periods and impair the well-being of those affected, include cancer as one of the most prevalent. Common types of cancer are breast, lung and bronchus, prostate, colon and rectum, skin melanoma, bladder, non-Hodgkin lymphoma, kidney and renal pelvis, endometrial, leukemia, pancreatic, thyroid, and liver cancers. As an example, data released in February 2024 by the Centers for Disease Control and Prevention (CDC)—a public health organization based in the United States—indicated that a rising number of Americans are dealing with multiple chronic conditions: 42% have two or more, while 12% face five or more. Because of this, the growing prevalence of chronic diseases is anticipated to drive the cancer biologics market in the years ahead.
Cancer biologics Market Segmentation And Category Breakdown
The cancer biologics market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Vaccines, Cell And Gene Therapy, Other Types
2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications
3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Vaccines: Therapeutic Cancer Vaccines, Preventive Cancer Vaccines
3) By Cell And Gene Therapy: CAR T-Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Oncolytic Virus Therapy
4) By Other Types: Cytokines, Growth Factors, Fusion Proteins
Cancer biologics Market Trends Driving Strategic Industry Expansion
Major players in the cancer biologics space are prioritizing the creation of cutting-edge treatments, including bispecific antibodies and biomarker-driven biologics, to boost therapeutic effectiveness and better zero in on particular cancer cells. Bispecific antibodies represent a next-generation biologic approach capable of engaging two separate epitopes or targets at once, whereas biomarker-guided biologics are engineered to precisely attack tumor cells identified through specific molecular indicators. As an example, in November 2024, as reported by Jazz Pharmaceuticals Public Limited Company, a Dublin-headquartered global biopharmaceutical firm, the U.S. Food & Drug Administration (FDA) granted accelerated approval for Ziihera (zanidatamab hrii) to treat adults with previously treated, unresectable or metastatic HER2 positive (IHC 3+) biliary tract cancer (BTC). This authorization marks the first and only dual HER2-targeted bispecific antibody to receive approval for this particular indication, thus extending the application of HER2-focused biologic therapy to a new cancer type beyond its previous scope.
Cancer biologics Market Competitive Analysis Of Major Industry Participants
Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.
Access The Complete Cancer biologics Market Report:
Cancer biologics Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
